| efforts | developing | vaccines against SARS-CoV-2 (count: 2) | |
|---|---|
| Overall, as the identified set of epitopes map identically to SARS-CoV-2, they present potentially useful candidates for guiding experimental efforts towards developing universal vaccines against SARS-CoV-2.
| |
| Overall, as the identified set of SARS-CoV epitopes map identically to SARS-CoV-2, they present potentially useful candidates for guiding experimental efforts towards developing vaccines against SARS-CoV-2.
| |
| research | aid | vaccine development for SARS-CoV-2 (count: 1) | |
| Due to this apparent similarity between the two viruses, previous research that has provided an understanding of protective immune responses against SARS-CoV may potentially be leveraged to aid vaccine development for SARS-CoV-2.
| |
| Our results | can narrow down | search for targets for vaccine against SARS-CoV-2 (count: 1) | |
| Our presented results can potentially narrow down the search for potent targets for an effective vaccine against SARS-CoV-2, and help guide experimental studies focused on vaccine development.
| |
| we | aid | vaccine development for SARS-CoV-2 (count: 1) | |
| Given the close genetic similarity between the structural proteins of SARS-CoV and SARS-CoV-2, we attempted to leverage immunological studies of the structural proteins of SARS-CoV to potentially aid vaccine development for SARS-CoV-2.
| |
| it | is urgent Under | circumstance of absence of vaccines against SARS-CoV-2 (count: 1) | |
| Under the current circumstance of the absence of the specific vaccines and medicines against SARS-CoV-2, it is urgent to discover effective therapies especially drugs to treat the resulting COVID-19 disease and prevent the virus from further spreading.
| |
| study | reported | analysis of 2019-nCoV genome evolution for vaccine development (count: 1) | |
| The present study reported detailed analysis of 2019-nCoV genome evolution and potential candidate peptides for vaccine development.
| |
| it | develop | 17 vaccine against disease caused by SARS-CoV-2 18 coronavirus (count: 1) | |
| To ultimately combat the emerging COVID-19 pandemic, it is desired to develop an 17 effective and safe vaccine against this highly contagious disease caused by the SARS-CoV-2 18 coronavirus.
-- reference not found! | |
| safety | efficacy of | COVID-19 88 vaccine development (count: 1) | |
| Therefore, novel strategies are needed to enhance the efficacy and safety of COVID-19 88 vaccine development.
-- reference not found! | |
| 98 | predict | COVID-19 protein 99 candidates for vaccine development (count: 1) | |
| In this study, we first surveyed the existing coronavirus vaccine development status, and 98 then applied the Vaxign RV and Vaxign-ML approaches to predict COVID-19 protein 99 candidates for vaccine development.
-- reference not found! | |
| provides | analysis for | vaccine development against COVID-19 (count: 1) | |
| Finally, the Vaxign RV framework also predicted 2 regions (position 251-260 and 209 329-337) in the MAC1 domain of nsp3 domain having high sequence similarity to the human 210 mono-ADP-ribosyltransferase PARP14 (NP_060024.of the potential SARS-CoV-2 antigens, which could induce protective 214 immunity, provides a timely analysis for the vaccine development against COVID-19.
-- reference not found! | |
| biotechnology | developing | vaccines against SARS-CoV-2 (count: 1) | |
| Medical biotechnology is important in developing vaccines against SARS-CoV-2.
-- Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2. biorxiv. 2020-02-27. | |
| objective | design | multi epitope peptide vaccine against COVID-19 (count: 1) | |
| Currently, there is no vaccine or approved treatment for this emerging infection; thus the objective of this study is to design a multi epitope peptide vaccine against COVID-19 using immunoinformatics approach.
| |
| peptides | were proposed for | designing of vaccine against COVID-19 (count: 1) | |
| In our present work, different peptides were proposed for the designing of vaccine against COVID-19 (Fig.
| |
| peptides | formulate | vaccine against COVID-19 (count: 1) | |
| Based on the aforementioned results and taking into consideration the high binding affinity to both MHC classes I and II, conservancy and population coverage, three peptides are strongly proposed to formulate a new vaccine against COVID-19.
| |
| Our findings | may contribute to | design of vaccine against COVID-19 (count: 1) | |
| Our findings may contribute to the design of an efficacious vaccine against COVID-19.
-- reference not found! | |
| peptide-HLA prediction tools | be suitable for | identification of epitopes relevant in vaccine against SARS-CoV-2 (count: 1) | |
| 1999) To assess whether current peptide-HLA prediction tools could be suitable for identification of epitopes relevant in a vaccine against SARS-CoV-2, we tested predicted binders from the netMHC tools, using a new MHC:peptide complex stability assay NeoScreen Ⓡ .
-- reference not found! | |
| contribution | development of | vaccine against SARS-CoV-2 (count: 1) | |
| We hope that this contribution will aid the development of a vaccine against SARS-CoV-2.
-- reference not found! | |
| study | design | possible subunit vaccines against SARS-CoV-2 virus (count: 1) | |
| This study was conducted to design possible epitope-based subunit vaccines against the SARS-CoV-2 virus using the approaches of reverse vaccinology and immunoinformatics.
| |
| experiment | design vaccine against | four proteins of SARS-CoV-2 phosphoprotein (count: 1) | |
| This experiment is carried out to design novel epitope-based vaccine against four proteins of SARS-CoV-2 i.e., nucleocapsid phosphoprotein which is responsible for genome packaging and viral assembly [96] ; surface glycoprotein that is responsible for membrane fusion event during viral entry [97] [98] ; ORF3a protein that is responsible for viral replication, characterized virulence, viral spreading and infection [99] and membrane glycoprotein which mediates the interaction of virions with cell receptors [100] using the approaches of reverse vaccinology.
| |
| experiment | develop | potential vaccines against Wuhan coronavirus (count: 1) | |
| The current experiment was conducted to develop potential vaccines against the Wuhan novel coronavirus (strain SARS-CoV-2) (Wuhan seafood market pneumonia virus) exploiting the strategies of reverse vaccinology (Figure 01 ).
| |
| potential subunit vaccines | were designed against | SARS-CoV-2 (count: 1) | |
| In this study, potential subunit vaccines were designed against the SARS-CoV-2 using various methods of reverse vaccinology and immunoinformatics.
| |
| they | vaccines against | 2019-nCoV (count: 1) | |
| As of the PHEIC declaration, 12 groups have announced that they are developing new vaccines against 2019-nCoV and seven others announced initiatives to develop new therapies [74] .
| |
| work | may shed light on | vaccine intervention for 2019-nCoV (count: 1) | |
| This timely work may shed light on the vaccine intervention for the emergent 2019-nCoV.
-- Identification of potential cross-protective epitope between a new type of coronavirus (2019-nCoV) and severe acute respiratory syndrome virus. Journal of Genetics and Genomics. 2020-01-30. | |
| findings | may provide | information for design of vaccines against SARS-CoV-2 (count: 1) | |
| These findings may provide valuable information for the rational design of vaccines against SARS-CoV-2.
-- Molecular immune pathogenesis and diagnosis of COVID-19. Journal of Pharmaceutical Analysis. 2020-03-05. | |